The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
The Multiple Myeloma Hub was pleased to speak to Rajshekhar Chakraborty, Herbert Irving Comprehensive Cancer Center, New York, US. We asked, What are the initial results of antibody–drug conjugate (ADC)-based combinations?
What are the initial results of ADC-based combinations?
Chakraborty begins by summarizing the results of the DREAMM-2 study, which investigated the use of an ADC, belantamab mafodotin, in relapsed/refractory multiple myeloma. Chakraborty then discusses belantamab mafodotin-based combinations, including that with pomalidomide and dexamethasone, and the benefits of using combinations rather than single agents.
